ARTICLE | Deals
Tizona searching for new partner after Gilead declines buyout option
Gilead retains ownership of nearly half of Tizona’s equity via $300M investment in 2020, but won’t take full control of anti-HLA-G antibody
February 7, 2024 7:56 PM UTC
Tizona is looking for a partner for its clinical anti-HLA-G antibody in the wake of Gilead’s decision not to exercise its option acquire the biotech under a 2020 deal.
A spokesperson for privately held Tizona Therapeutics Inc. confirmed to BioCentury that Gilead Sciences Inc. (NASDAQ:GILD) “made a strategic business decision to forego its exclusive option to acquire Tizona, while retaining its 49.9% equity interest” in the biotech. Gilead paid Tizona $300 million up front for the equity stake and option...